Ixabepilone: a new active chemotherapy in the treatment of breast cancer. - Inserm - Institut national de la santé et de la recherche médicale Access content directly
Journal Articles Womens Health (Lond Engl) Year : 2009

Ixabepilone: a new active chemotherapy in the treatment of breast cancer.

Abstract

Ixabepilone (BMS247550) is a semisynthetic derivative of the natural product that optimizes the properties observed with epothilone B. This compound has some similarities with taxanes in targeting and stabilizing microtubules, but it also has major differences. Interestingly, ixabepilone was evaluated in patients with well-characterized resistance to taxanes and was able to overcome the overexpression of multidrug resistance and was unaffected by mutations in the beta-tubulin genes. The interest in ixabepilone was clinically confirmed in Phase II and III clinical studies, which have demonstrated a strong activity in patients with metastatic breast cancer resistant to taxanes and in patients suffering from other types of chemoresistant tumors.

Domains

Immunology

Dates and versions

inserm-00484429 , version 1 (18-05-2010)

Identifiers

Cite

Cristian Villanueva, Antoine Thiery Vuillemin, Martin Demarchi, Fernando Bazan, Loïc Chaigneau, et al.. Ixabepilone: a new active chemotherapy in the treatment of breast cancer.. Womens Health (Lond Engl), 2009, 5 (2), pp.115-21. ⟨10.2217/17455057.5.2.115⟩. ⟨inserm-00484429⟩

Collections

INSERM UNIV-FCOMTE
56 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More